<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acute viral gastroenteritis in children in resource-abundant countries: Management and prevention</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acute viral gastroenteritis in children in resource-abundant countries: Management and prevention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acute viral gastroenteritis in children in resource-abundant countries: Management and prevention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Miguel G O'Ryan, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">B UK Li, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Diane Blake, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 23, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The prevention and treatment of viral gastroenteritis in children in resource-abundant countries will be reviewed here. The epidemiology, clinical features, and diagnosis of acute viral gastroenteritis in children in resource-abundant countries; acute diarrhea in children in resource-limited countries; and chronic diarrhea in children are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5984.html" rel="external">"Acute viral gastroenteritis in children in resource-abundant countries: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13956.html" rel="external">"Approach to the child with acute diarrhea in resource-limited settings"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5877.html" rel="external">"Overview of the causes of chronic diarrhea in children in resource-abundant settings"</a> and  <a class="medical medical_review" href="/z/d/html/5881.html" rel="external">"Approach to chronic diarrhea in children &gt;6 months in resource-abundant settings"</a> and  <a class="medical medical_review" href="/z/d/html/5878.html" rel="external">"Persistent diarrhea in children in resource-limited settings"</a>.)</p><p></p><p class="headingAnchor" id="H109219533"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>Acute gastroenteritis is a clinical syndrome often defined by increased stool frequency (eg, ≥3 loose or watery stools in 24 hours or a number of loose/watery bowel movements that exceeds the child's usual number of daily bowel movements by two or more), with or without vomiting or fever [<a href="#rid1">1-4</a>]. It usually lasts less than one week and not longer than two weeks. Diarrhea that lasts &gt;14 days is "persistent" or "chronic." Diarrhea that recurs after seven days without diarrhea is "recurrent."</p><p>Acute viral gastroenteritis is caused by a viral pathogen. Acute gastroenteritis also may be caused by bacteria and parasites. (See  <a class="medical medical_review" href="/z/d/html/5984.html" rel="external">"Acute viral gastroenteritis in children in resource-abundant countries: Clinical features and diagnosis", section on 'Etiology'</a> and  <a class="medical medical_review" href="/z/d/html/5984.html" rel="external">"Acute viral gastroenteritis in children in resource-abundant countries: Clinical features and diagnosis", section on 'Bacterial or parasitic gastroenteritis'</a>.)</p><p class="headingAnchor" id="H236718105"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Acute viral gastroenteritis usually is self-limited. It is treated with supportive measures (eg, fluid repletion and unrestricted diet) [<a href="#rid1">1,3</a>]. Antimicrobial agents are not indicated in the management of acute viral gastroenteritis. No specific antiviral agents are available, and other antimicrobial agents are ineffective and associated with increased costs and potential for antimicrobial resistance.</p><p>The recommendations provided below are generally consistent with those provided by the Centers for Disease Control and Prevention (CDC), the Infectious Diseases Society of America (IDSA), the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN), the European Society for Pediatric Infectious Diseases, and other professional organizations [<a href="#rid1">1-3,5,6</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Severity assessment</span></p><p class="headingAnchor" id="H344662349"><span class="h3">Degree of volume depletion</span><span class="headingEndMark"> — </span>The severity of acute gastroenteritis is determined by the degree of volume depletion  (<a class="graphic graphic_table graphicRef76198" href="/z/d/graphic/76198.html" rel="external">table 1</a>) [<a href="#rid1">1,3</a>]. Weight loss, dry mucous membranes, prolonged capillary refill time, loss of skin turgor, and increased and deep respiratory pattern are the best individual signs of hypovolemia. Other important signs that require immediate attention include increased pulse, diminished systolic and/or diastolic blood pressure, and sunken fontanel (in children whose fontanel remains open)  (<a class="graphic graphic_table graphicRef76198" href="/z/d/graphic/76198.html" rel="external">table 1</a>). Fever is common in viral gastroenteritis and can aggravate loss of fluids, particularly if high (eg, ≥39°C [102.2°F]). (See  <a class="medical medical_review" href="/z/d/html/6142.html" rel="external">"Clinical assessment of hypovolemia (dehydration) in children", section on 'Clinical assessment'</a>.)</p><p>Laboratory studies to evaluate the severity of hypovolemia are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6142.html" rel="external">"Clinical assessment of hypovolemia (dehydration) in children", section on 'Laboratory testing'</a>.)</p><p class="headingAnchor" id="H344662030"><span class="h3">Indications for hospitalization</span><span class="headingEndMark"> — </span>Indications for hospitalization of children with acute viral gastroenteritis include [<a href="#rid1">1,2,7,8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Shock (see  <a class="medical medical_review" href="/z/d/html/6396.html" rel="external">"Initial evaluation of shock in children"</a> and  <a class="medical medical_review" href="/z/d/html/6397.html" rel="external">"Shock in children in resource-abundant settings: Initial management"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe volume depletion  (<a class="graphic graphic_table graphicRef76198" href="/z/d/graphic/76198.html" rel="external">table 1</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Moderate volume depletion with refusal of oral fluids</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical deterioration</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intractable or bilious vomiting</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Failure of oral rehydration</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neurologic abnormalities (eg, lethargy, seizures)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Possibility of severe illness or condition other than acute gastroenteritis that requires specific therapy (eg, bowel obstruction  (<a class="graphic graphic_table graphicRef58814" href="/z/d/graphic/58814.html" rel="external">table 2</a>)) (see  <a class="medical medical_review" href="/z/d/html/5984.html" rel="external">"Acute viral gastroenteritis in children in resource-abundant countries: Clinical features and diagnosis", section on 'Differential diagnosis'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inability to assure adequate home management and outpatient follow-up</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Supportive treatment</span><span class="headingEndMark"> — </span>Acute viral gastroenteritis usually is self-limited. It is treated with supportive measures [<a href="#rid1">1,3</a>]. Fluid repletion and replacement of ongoing fluid losses are the goals of therapy, whether the child is managed at home, in the emergency department, or in the hospital.</p><p class="headingAnchor" id="H13"><span class="h3">Fluid repletion and maintenance</span><span class="headingEndMark"> — </span>Initial therapy is directed toward correcting fluid deficit and electrolyte imbalance. Fluid repletion is based upon the degree of hypovolemia (dehydration)  (<a class="graphic graphic_table graphicRef76198" href="/z/d/graphic/76198.html" rel="external">table 1</a>). Intravenous (IV) fluids should be administered if dehydration is severe or if the patient is unable to take oral solutions. (See  <a class="medical medical_review" href="/z/d/html/6142.html" rel="external">"Clinical assessment of hypovolemia (dehydration) in children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe dehydration</strong> – Severe hypovolemia requires rapid isotonic fluid resuscitation, which is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6103.html" rel="external">"Treatment of hypovolemia (dehydration) in children in resource-abundant settings"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild to moderate dehydration</strong> – Oral rehydration therapy (ORT) is the preferred first-line treatment for fluid and electrolyte losses in children with mild to moderate dehydration from acute gastroenteritis. (See  <a class="medical medical_review" href="/z/d/html/6129.html" rel="external">"Oral rehydration therapy", section on 'Clinical management'</a>.)</p><p></p><p class="headingAnchor" id="H14"><span class="h3">Diet</span><span class="headingEndMark"> — </span>We recommend resumption of an age-appropriate diet as tolerated as soon as rehydration is complete, in agreement with the CDC, IDSA, ESPGHAN, and other professional organizations [<a href="#rid1">1-3,5,6,8</a>]. Breastfeeding can continue during diarrhea.</p><p>Within the age-appropriate diet, complex carbohydrates, lean meats, yogurt, fruits, and vegetables are better tolerated than foods containing high levels of fats and simple sugars [<a href="#rid3">3</a>]. Foods high in simple sugars (eg, sugar sweetened beverages, some fruit juices) may increase stool output and the risk of hyponatremia because they increase the osmotic load and contain low concentrations of sodium and potassium [<a href="#rid2">2,3,9</a>]. Although commonly recommended in the past, the clear liquid and "BRAT" (bananas, rice, applesauce, and toast) diets are unnecessarily restrictive and provide suboptimal nutrition [<a href="#rid1">1,3</a>].</p><p>A meta-analysis of randomized trials of early versus late refeeding (within 12 hours of the start of rehydration or after 12 hours from the start of rehydration) in children with diarrhea found no difference between the groups in the number of children who needed unscheduled IV fluids, had episodes of vomiting, or developed persistent diarrhea [<a href="#rid10">10</a>]. Breastfeeding during oral rehydration appears to reduce the number, volume, and duration of diarrheal stools [<a href="#rid11">11</a>].</p><p>The lactose intolerance associated with acute viral gastroenteritis usually is mild and self-limiting [<a href="#rid12">12,13</a>], although a lactose-free diet may reduce the duration of diarrhea and the risk of treatment failure among children who are not breastfed. In a 2013 meta-analysis of 16 randomized and quasi-randomized trials from high- or middle-income countries (1467 patients), a lactose-free diet reduced the mean duration of diarrhea by 17.7 hours (95% CI 10.2-25.3 hours) [<a href="#rid14">14</a>]; however, most of the trials were inadequately blinded, and there was significant heterogeneity in patient populations. In pooled analysis of 18 trials (1470 patients), lactose-free diets also appeared to reduce the risk of treatment failure, which was variably defined as continued or worsening diarrhea/vomiting, need for additional rehydration, or continued weight loss (relative risk [RR] 0.52, 95% CI 0.39-0.68). Although not routinely recommended, a lactose-free diet may be warranted for severe cases requiring hospitalization. Breastfeeding and infant formula can be resumed as tolerated when severe dehydration is corrected and can continue without change as tolerated for the child with mild to moderate dehydration.</p><p class="headingAnchor" id="H236717964"><span class="h2">Symptomatic therapy</span><span class="headingEndMark"> — </span>Viral gastroenteritis is usually an acute and self-limited disease that <strong>does not</strong> require pharmacologic therapy.</p><p class="headingAnchor" id="H236717971"><span class="h3">Antidiarrheal agents</span><span class="headingEndMark"> — </span>We suggest that antidiarrheal agents not be routinely administered in the treatment of acute viral gastroenteritis. High-quality evidence of efficacy is lacking for most antidiarrheal agents and there is a potential for serious side effects, as discussed below [<a href="#rid1">1,3,7</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antimotility drugs</strong> – Opiate receptor agonists, such as <a class="drug drug_pediatric" data-topicid="12561" href="/z/d/drug information/12561.html" rel="external">loperamide</a> and <a class="drug drug_pediatric" data-topicid="13237" href="/z/d/drug information/13237.html" rel="external">diphenoxylate-atropine</a> combinations, reduce intestinal motility. These drugs have potentially severe side effects, including lethargy, paralytic ileus, toxic megacolon, central nervous system depression, coma, and even death in less than 1 percent [<a href="#rid15">15-18</a>]. In addition, because they delay transit time, they can prolong the course of bacterial diarrheas, such as that caused by <em>Shigella</em> and <em>Escherichia coli</em> [<a href="#rid19">19,20</a>]. Whether this also is true in viral gastroenteritis is unknown.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antisecretory drugs</strong> – Antisecretory drugs include <a class="drug drug_pediatric" data-topicid="101045" href="/z/d/drug information/101045.html" rel="external">bismuth subsalicylate</a> and racecadotril (acetorphan).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="101045" href="/z/d/drug information/101045.html" rel="external">Bismuth subsalicylate</a> requires frequent dosing with limited efficacy [<a href="#rid21">21</a>] and has potential toxicity from salicylate absorption [<a href="#rid22">22</a>]. It should not be routinely used in the management of children with gastroenteritis [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Racecadotril is an enkephalinase inhibitor with antisecretory actions. Whether it is beneficial in the management of acute viral gastroenteritis in children is uncertain. Although racecadotril appears to be safe, meta-analyses of randomized and quasi-randomized trials have inconsistent findings related to benefit, which may be related to inclusion of different trials [<a href="#rid18">18,23,24</a>]. The overall quality of the evidence is limited by inconsistent results, heterogeneity in patient populations and outcome measures, and methodologic shortcomings (eg, lack of concealment or blinding) [<a href="#rid18">18,23,24</a>].</p><p></p><p class="bulletIndent2">The European guidelines suggest that racecadotril "can be considered" in the management of acute gastroenteritis [<a href="#rid1">1</a>]. Racecadotril is not available in the United States.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adsorbents</strong> – Adsorbents (eg, hydrated aluminomagnesium silicates such as smectite/diosmectite and attapulgite, and kaolin-pectin) have the potential to bind digestive mucus and toxins, and reduce water loss [<a href="#rid25">25,26</a>].</p><p></p><p class="bulletIndent1">Smectite/diosmectite is an adsorbent that is commonly used in several European countries. A network meta-analysis of randomized and quasi-randomized trials comparing interventions for acute diarrhea and gastroenteritis found low-quality evidence that smectite reduced the duration of diarrhea by 23.9 hours (95% CI 17.0-30.8), without increased risk of adverse effects, compared with standard care or placebo [<a href="#rid18">18</a>]; however, another meta-analysis found it had no effect on hospitalization rate or need for intravenous therapy [<a href="#rid27">27</a>]. Combined therapy with smectite and zinc is discussed below. (See <a class="local">'Zinc'</a> below.)</p><p></p><p class="bulletIndent1">The European guidelines suggest that diosmectite "can be considered" in the management of acute gastroenteritis [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1">There is no evidence from high-quality trials that attapulgite or kaolin-pectin is effective in the treatment of acute gastroenteritis in children [<a href="#rid1">1,5,18</a>].</p><p></p><p class="headingAnchor" id="H22"><span class="h3">Antiemetic agents</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ondansetron</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Children who are not dehydrated</strong> – For the routine management of children with acute viral gastroenteritis who are not dehydrated, we suggest against <a class="drug drug_pediatric" data-topicid="12659" href="/z/d/drug information/12659.html" rel="external">ondansetron</a> and other antiemetics. The benefits are unproven [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Children with mild to moderate dehydration and vomiting that interferes with ORT</strong> – For children ≥6 months of age with suspected viral gastroenteritis, mild to moderate dehydration, and vomiting that interferes with ORT, we suggest <a class="drug drug_pediatric" data-topicid="12659" href="/z/d/drug information/12659.html" rel="external">ondansetron</a>. Compared with placebo and other antiemetic agents, ondansetron stops vomiting and facilitates ORT; it also reduces the need for IV fluids [<a href="#rid29">29-32</a>]. (See  <a class="medical medical_review" href="/z/d/html/6129.html" rel="external">"Oral rehydration therapy"</a>.)</p><p></p><p class="bulletIndent2">The typical regimen is a single oral dose of <a class="drug drug_pediatric" data-topicid="12659" href="/z/d/drug information/12659.html" rel="external">ondansetron</a> 0.15 mg/kg (maximum dose of 8 mg). Multiple doses and IV administration can increase the risk of diarrhea and other adverse effects (eg, arrhythmia) [<a href="#rid33">33-35</a>]. Repeated doses have not proven beneficial [<a href="#rid29">29,36</a>].</p><p></p><p class="bulletIndent2">In a systematic review comparing a single dose of oral <a class="drug drug_pediatric" data-topicid="12659" href="/z/d/drug information/12659.html" rel="external">ondansetron</a> with placebo, ondansetron increased cessation of vomiting within eight hours (82 versus 66 percent, RR 1.41, 95% CI 1.19-1.68; nine trials, 1748 participants), reduced ORT failure (19 versus 45 percent, RR 0.43, 95% CI 0.34-0.55; five trials, 679 participants), reduced the need for IV fluid (8 versus 19 percent, RR 0.44, 95% CI 0.34-0.57; eight trials, 1662 participants), and reduced rates of hospitalization within eight hours (7 versus 14 percent, RR 0.49, 95% CI 0.32-0.75; five trials, 823 participants) [<a href="#rid32">32</a>]. In a network meta-analysis of 24 randomized trials (3482 participants), ondansetron was superior to other antiemetics (<a class="drug drug_general" data-topicid="8777" href="/z/d/drug information/8777.html" rel="external">domperidone</a>, <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a>, <a class="drug drug_pediatric" data-topicid="13234" href="/z/d/drug information/13234.html" rel="external">dimenhydrinate</a>, <a class="drug drug_pediatric" data-topicid="13341" href="/z/d/drug information/13341.html" rel="external">granisetron</a>, <a class="drug drug_pediatric" data-topicid="12602" href="/z/d/drug information/12602.html" rel="external">metoclopramide</a>) and placebo in relieving vomiting and preventing the need for IV fluids and hospitalization in children with acute gastroenteritis [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent2">A single dose of oral <a class="drug drug_pediatric" data-topicid="12659" href="/z/d/drug information/12659.html" rel="external">ondansetron</a> appears to be safe in children without risk factors for arrhythmia [<a href="#rid34">34</a>]. In meta-analyses of randomized trials, the adverse effects of ondansetron generally were similar to those of placebo, although cases of urticaria and increased frequency of diarrhea have been reported [<a href="#rid30">30,31</a>]. When used for other indications, common adverse effects of ondansetron include headache and constipation [<a href="#rid37">37-40</a>].</p><p></p><p class="bulletIndent2"><a class="drug drug_pediatric" data-topicid="12659" href="/z/d/drug information/12659.html" rel="external">Ondansetron</a> does not appear to mask the diagnosis of serious causes of vomiting. In large retrospective studies, receipt of ondansetron or a prescription for ondansetron in the emergency department was not associated with increased rates of hospitalization or return visit within 72 hours for a diagnosis other than acute gastroenteritis (eg, appendicitis, intussusception, bacteremia, pyelonephritis, small bowel obstruction, intracranial tumor, meningitis) [<a href="#rid41">41-43</a>].</p><p></p><p class="bulletIndent2"><a class="drug drug_pediatric" data-topicid="12659" href="/z/d/drug information/12659.html" rel="external">Ondansetron</a> should not be used in patients who have congenital long QT syndrome or who are at risk for malignant hyperthermia. Serious potential adverse effects of first-generation selective serotonin 5-HT<sub>3</sub> antagonists such as ondansetron include excessive serotonergic effect and arrhythmia [<a href="#rid44">44-46</a>]. Electrocardiogram monitoring may be warranted for children at risk for corrected QT interval (QTc) prolongation, including those with hypokalemia or hypomagnesemia, heart failure, or bradyarrhythmias, and in patients taking other medications that increase the risk of QTc prolongation  (<a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">table 3</a>) [<a href="#rid34">34,47</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Children with severe dehydration</strong> – Children with severe dehydration require IV hydration. (See  <a class="medical medical_review" href="/z/d/html/6103.html" rel="external">"Treatment of hypovolemia (dehydration) in children in resource-abundant settings", section on 'Emergency fluid repletion phase'</a>.)</p><p></p><p class="bulletIndent1">Society guideline recommendations for <a class="drug drug_pediatric" data-topicid="12659" href="/z/d/drug information/12659.html" rel="external">ondansetron</a> are inconsistent. The IDSA guidelines for the management of infectious diarrhea indicate that ondansetron may reduce the need for hospitalization for rehydration but increase stool volume [<a href="#rid6">6</a>]. They do not routinely recommend ondansetron for children younger than four years. The European Guidelines indicate that ondansetron (oral or IV) may be effective in young children with vomiting related to acute gastroenteritis, but additional safety information is necessary [<a href="#rid1">1</a>]. The Canadian Paediatric Society recommends that a single dose of oral ondansetron be considered for children ≥6 months age who present to the emergency department with vomiting related to suspected acute gastroenteritis who have mild to moderate dehydration or have failed ORT [<a href="#rid48">48</a>]. (See <a class="local">'Society guideline links'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other antiemetics</strong> – We avoid other antiemetics (eg, phenothiazines, antihistamines, dopamine receptor antagonists, glucocorticoids) in the treatment of acute gastroenteritis in children. Evidence to support their use is lacking and they may have adverse effects [<a href="#rid31">31,49-51</a>].</p><p></p><p class="bulletIndent1">Phenothiazines (eg, <a class="drug drug_pediatric" data-topicid="12735" href="/z/d/drug information/12735.html" rel="external">promethazine</a>, <a class="drug drug_pediatric" data-topicid="12602" href="/z/d/drug information/12602.html" rel="external">metoclopramide</a>, <a class="drug drug_pediatric" data-topicid="12734" href="/z/d/drug information/12734.html" rel="external">prochlorperazine</a>) have the potential to cause extrapyramidal reactions, including dystonic reaction and oculogyric crisis [<a href="#rid52">52</a>]. Promethazine is associated with an increased risk of respiratory depression. It should not be used in children younger than two years and should be used with caution in older children; concomitant administration of other drugs with respiratory depressant effects should be avoided [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1">Antihistamines (eg, <a class="drug drug_pediatric" data-topicid="13234" href="/z/d/drug information/13234.html" rel="external">dimenhydrinate</a>) may be associated with adverse effects (eg, sedation, dizziness, restlessness). In a network meta-analysis of antiemetics for acute gastroenteritis in children, dimenhydrinate was the only antiemetic that had more side effects than placebo, predominantly somnolence [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8777" href="/z/d/drug information/8777.html" rel="external">Domperidone</a> (a dopamine receptor antagonist) has been associated with serious ventricular arrhythmias and sudden cardiac death [<a href="#rid54">54,55</a>].</p><p></p><p class="headingAnchor" id="H344662588"><span class="h3">Probiotics and prebiotics</span><span class="headingEndMark"> — </span>Probiotics are live microbes that have the potential to benefit the host by altering intestinal flora. Prebiotics are substrates that are selectively utilized by host microorganisms conferring a health benefit [<a href="#rid56">56</a>]; examples of prebiotics include fructooligosaccharides and inulin.</p><p>Probiotics have been considered as an adjunct to rehydration therapy [<a href="#rid57">57</a>]. Although we generally discourage probiotics and prebiotics, we make decisions on a case-by-case basis in children with acute viral gastroenteritis after discussing the potential benefits and harms with the patient's caregivers.</p><p>The evidence of benefit for specific strains is inconsistent and generally of low certainty [<a href="#rid57">57,58</a>]. A systematic review of randomized trials comparing a specified probiotic with placebo or no probiotic concluded that it was uncertain whether probiotics reduced the mean duration of diarrhea and that probiotics probably make little difference in the number of people who have diarrhea for ≥48 hours [<a href="#rid58">58</a>]. Although meta-analyses of randomized trials of specific probiotic strains suggest potential benefit in reducing the duration of diarrhea (by approximately one day) without increasing the risk of adverse effects [<a href="#rid59">59-61</a>], the included trials had marked heterogeneity (eg, dose, age, severity, geographic region) and most had high risk of bias [<a href="#rid58">58,62</a>]. In meta-analyses that included only trials of <a class="drug drug_pediatric" data-topicid="13404" href="/z/d/drug information/13404.html" rel="external">Lactobacillus</a> rhamnosus GG at low risk of bias, no benefit was detected [<a href="#rid59">59,63</a>].</p><p>The benefit, if any, appears to be affected by the strain(s), dose, possibly the pathogen, and combination with prebiotics or other agents [<a href="#rid5">5,7,18,64-66</a>]. In pathogen-specific secondary analysis of patient-level data from two randomized trials in North America, neither <em>L. rhamnosus</em> GG nor a combination of <em>L. rhamnosus</em>/R0011 and <a class="drug drug_pediatric" data-topicid="13404" href="/z/d/drug information/13404.html" rel="external">Lactobacillus</a> helveticus R0052 was found to decrease the severity of diarrhea due to the most common pathogens in children age 3 to 48 months; among children with adenovirus diarrhea, combination <em>L. rhamnosus</em>/R0011/<em>L. helveticus</em> R0052 appeared to reduce the number of diarrheal episodes [<a href="#rid67">67</a>]. The benefit also may be related to the source of the particular preparation, which affects quality control and shelf-life [<a href="#rid65">65</a>].</p><p>Safety is another factor to consider in the decision to use probiotics. The US Food and Drug Administration does not evaluate probiotic products, which may contain unlabeled ingredients or species that differ from those indicated on the label or be contaminated with fungi or other pathogens; the reporting of harms in randomized trials is often inadequate or lacking [<a href="#rid3">3,68-72</a>]. In addition, probiotics and prebiotics are not typically covered by insurance.</p><p>The optimal timing for administration is uncertain. The suggestion that effectiveness is increased with early administration is not supported by randomized trials [<a href="#rid73">73-75</a>].</p><p>If clinicians and caregivers decide to use probiotic/prebiotics, the ESPGHAN Working Group on probiotics/prebiotics suggests one of the following strains [<a href="#rid57">57,76</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9481" href="/z/d/drug information/9481.html" rel="external">Saccharomyces boulardii</a> 250 to 750 mg (10<sup>9</sup> to 10<sup>10</sup> colony-forming units [CFU])/day (typically for five to seven days) [<a href="#rid18">18,60</a>]</p><p></p><p class="bulletIndent1">Combined therapy with <em>S. boulardii</em> and zinc is discussed below. (See <a class="local">'Zinc'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>L. rhamnosus</em> GG &gt;10<sup>10</sup> CFU/day for five to seven days [<a href="#rid59">59</a>] </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>Limosilactobacillus reuteri</em> DSM 17938 1 to 4 x 10<sup>8</sup> CFU/day for five days [<a href="#rid61">61</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>L. rhamnosus</em> 19070-2 combined with <em>L. reuteri</em> DSM 12246 2 x 10<sup>10</sup> CFU of each strain/day for five days</p><p></p><p>The ESPGHAN makes a strong recommendation against <em>L. helveticus</em> R0052 combined with <em>L. rhamnosus</em> R0011 based on moderate certainty evidence that the combination has no effect on duration of diarrhea and a weak recommendation against <em>Bacillus clausii</em> strains based on low certainty evidence [<a href="#rid57">57,77</a>].</p><p>The IDSA guidelines suggest that probiotics may be offered to reduce symptoms' severity in children with infectious diarrhea [<a href="#rid6">6</a>]. The 2014 European guidelines suggest that administration of effective probiotic strains "may be considered" in children admitted with acute gastroenteritis [<a href="#rid1">1</a>]. Other professional groups acknowledge the low-quality evidence suggesting a benefit to probiotics (specifically <em>L. rhamnosus</em> GG ) early in the course of acute viral gastroenteritis, but do not make recommendations for or against their use [<a href="#rid5">5,7,64</a>].</p><p class="headingAnchor" id="H236717984"><span class="h3">Zinc</span><span class="headingEndMark"> — </span>We suggest not using zinc (alone or in combination with other agents) in the management of acute viral gastroenteritis in children in resource-abundant countries, where zinc deficiency is rare and no benefit from zinc is expected [<a href="#rid1">1</a>]. In a network meta-analysis of randomized and quasi-randomized trials comparing interventions for acute diarrhea and gastroenteritis, zinc was not found to be effective in reducing the duration of diarrhea in children in high-income countries [<a href="#rid18">18</a>]. Although there was moderate-quality evidence that the combination of zinc and <em>S. boulardii</em> or zinc and smectite reduced the duration of diarrhea by &gt;35 hours, all of the included trials were performed in low- and middle-income countries.</p><p>Zinc supplementation for the treatment of children with acute diarrhea in resource-poor countries is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5354.html" rel="external">"Zinc deficiency and supplementation in children", section on 'Treatment of acute or persistent diarrhea'</a>.)</p><p class="headingAnchor" id="H344662356"><span class="h2">Response to therapy</span></p><p class="headingAnchor" id="H1818312028"><span class="h3">Monitoring response</span><span class="headingEndMark"> — </span>The child must be evaluated to ensure the volume status is correcting properly. Response to fluid therapy is assessed by measuring body weight with a goal of:</p><p class="bulletIndent1"><span class="glyph">●</span>Return to premorbid body weight for children with acute viral gastroenteritis complicated by volume depletion</p><p class="bulletIndent1"><span class="glyph">●</span>Maintenance of body weight for children with acute viral gastroenteritis without volume depletion</p><p></p><p>Serum electrolytes should be monitored in children with hypernatremia or hyponatremia. It is important to correct these electrolyte abnormalities at the proper rate. Monitoring response to therapy for children receiving IV fluids is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6103.html" rel="external">"Treatment of hypovolemia (dehydration) in children in resource-abundant settings"</a> and  <a class="medical medical_review" href="/z/d/html/2320.html" rel="external">"Acid-base and electrolyte abnormalities with diarrhea"</a> and  <a class="medical medical_review" href="/z/d/html/14276.html" rel="external">"Hypernatremia in children", section on 'Rate of correction'</a>.)</p><p class="headingAnchor" id="H1818311899"><span class="h3">Expected response</span><span class="headingEndMark"> — </span>With appropriate fluid repletion, maintenance of hydration, and timely reintroduction of an age-appropriate diet, most children with acute viral gastroenteritis recover completely. Parents and caregivers should understand that diarrhea may last for ≥7 days and may continue after discharge from medical care.</p><p class="headingAnchor" id="H1818312034"><span class="h3">Failure to respond or worsening</span><span class="headingEndMark"> — </span>Conditions other than acute viral gastroenteritis must be considered in children who fail to respond to fluid therapy or whose clinical condition worsens despite fluid therapy. The extent and pace of the evaluation for these conditions depends upon the clinical status of the child. It is particularly important to consider life-threatening conditions that can mimic acute viral gastroenteritis, including those listed below (see  <a class="medical medical_review" href="/z/d/html/5984.html" rel="external">"Acute viral gastroenteritis in children in resource-abundant countries: Clinical features and diagnosis", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/6456.html" rel="external">"Diagnostic approach to diarrhea in children in resource-abundant settings"</a> and  <a class="medical medical_review" href="/z/d/html/5902.html" rel="external">"Approach to the infant or child with nausea and vomiting"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Intestinal obstruction (eg, appendicitis, intussusception, pyloric stenosis, malrotation) (see  <a class="medical medical_review" href="/z/d/html/6479.html" rel="external">"Acute appendicitis in children: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5898.html" rel="external">"Intussusception in children"</a> and  <a class="medical medical_review" href="/z/d/html/5890.html" rel="external">"Infantile hypertrophic pyloric stenosis"</a> and  <a class="medical medical_review" href="/z/d/html/6477.html" rel="external">"Intestinal malrotation in children"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic disease (including diabetic ketoacidosis) (see  <a class="medical medical_review" href="/z/d/html/5809.html" rel="external">"Diabetic ketoacidosis in children: Clinical features and diagnosis", section on 'Clinical features'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>Clostridioides difficile </em>colitis and/or pseudomembranous colitis (see  <a class="medical medical_review" href="/z/d/html/6048.html" rel="external">"<i>Clostridioides difficile</i> infection in children: Clinical features and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Enterocolitis and toxic megacolon (which may occur as a complication of Hirschsprung disease, inflammatory bowel disease, and infectious colitis) (see  <a class="medical medical_review" href="/z/d/html/1381.html" rel="external">"Toxic megacolon"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Congenital secretory and osmotic diarrheas (see  <a class="medical medical_review" href="/z/d/html/117487.html" rel="external">"Approach to chronic diarrhea in neonates and young infants (&lt;6 months)"</a>)</p><p></p><p class="headingAnchor" id="H1818312043"><span class="h3">Persistent symptoms</span><span class="headingEndMark"> — </span>Conditions that cause persistent, recurrent, or chronic diarrhea should be considered in children who continue to have diarrhea for longer than seven days. Causes of chronic diarrhea and the approach to the evaluation of chronic diarrhea in children in resource-abundant countries are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5877.html" rel="external">"Overview of the causes of chronic diarrhea in children in resource-abundant settings"</a> and  <a class="medical medical_review" href="/z/d/html/5881.html" rel="external">"Approach to chronic diarrhea in children &gt;6 months in resource-abundant settings"</a>.)</p><p class="headingAnchor" id="H1818311933"><span class="h2">Discharge from the medical setting</span><span class="headingEndMark"> — </span>For children who are admitted to the hospital for IV fluid repletion or cared for in a medical setting (eg, emergency department, office), minimum criteria for discharge to home include [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Repletion of fluid status, indicated by weight gain and improvement in clinical status</p><p class="bulletIndent1"><span class="glyph">●</span>Ability to meet maintenance fluid needs with oral intake (eg, volume of oral intake equals or surpasses output) (see  <a class="medical medical_review" href="/z/d/html/6122.html" rel="external">"Maintenance intravenous fluid therapy in children"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Follow-up (in person or by phone) is arranged</p><p class="bulletIndent1"><span class="glyph">●</span>Parents/caregivers understand indications to return to medical care</p><p></p><p class="headingAnchor" id="H236717312"><span class="h1">PREVENTION</span></p><p class="headingAnchor" id="H1550715022"><span class="h2">Vaccines</span><span class="headingEndMark"> — </span>Administration of rotavirus vaccine is the most effective way to prevent rotavirus gastroenteritis in children  (<a class="graphic graphic_figure graphicRef58821" href="/z/d/graphic/58821.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/z/d/html/6023.html" rel="external">"Rotavirus vaccines for infants"</a>.)</p><p>Several norovirus vaccines are in clinical trials [<a href="#rid78">78-81</a>].</p><p class="headingAnchor" id="H586787114"><span class="h2">General measures</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Handwashing</strong> – Handwashing with soap by caregiver and child, especially after diaper changes or contact with vomitus, may decrease the spread of the viruses that cause acute gastroenteritis [<a href="#rid82">82-85</a>]. Commonly used alcohol-based hand sanitizers have little effect on norovirus, the most commonly detected pathogen in children hospitalized for acute gastroenteritis in the United States [<a href="#rid86">86-89</a>]. A meta-analysis, not limited to viral gastroenteritis, suggested that handwashing with soap reduces diarrheal risk by 47 percent [<a href="#rid83">83</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diaper changing</strong> – Diaper changing areas should be separate from food preparation areas. Diapers should be disposed of directly in the changing area and put in occlusive bags before moving outside the home. A wipe-down fluid for the changing area should be used; a reasonable choice is diluted household bleach prepared in a spray bottle – alcohol solutions have little effect on norovirus.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Water purification</strong> – Disinfection of water obtained from unsafe water sources is an important means of prevention of gastroenteritis [<a href="#rid90">90</a>]. Methods suitable in the home for disinfection include boiling water for 10 minutes or addition of chlorine-containing tablets or solutions. Application of these interventions may be limited by cost or acceptability [<a href="#rid91">91</a>].</p><p></p><p class="headingAnchor" id="H667603798"><span class="h2">Return to child care or school</span><span class="headingEndMark"> — </span>Resolution of diarrhea and absence of vomiting are the major factors that determine when the child can return to child care, including church nurseries and similar settings, or school. In general, more restrictive exclusion recommendations are associated with decreased risk to other children.</p><p>The American Academy of Pediatrics (AAP) Committee on Infectious Diseases provides the following guidance for returning to child care or school [<a href="#rid92">92,93</a>]:</p><p>Children with diarrhea may attend child care or school, provided that:</p><p class="bulletIndent1"><span class="glyph">●</span>Stools are contained in the diaper (for infants)</p><p class="bulletIndent1"><span class="glyph">●</span>The child has no accidents using the toilet (for older children)</p><p class="bulletIndent1"><span class="glyph">●</span>Stool frequency is less than two stools greater than the child's normal stool frequency</p><p></p><p>Children who have had ≥2 episodes of vomiting related to acute gastroenteritis in the previous 24 hours should be excluded until vomiting has resolved.</p><p>The National Institute for Health and Care Excellence (NICE) recommends that children should be excluded from child care or school until ≥48 hours after the last episode of diarrhea or vomiting [<a href="#rid2">2,94</a>].</p><p class="headingAnchor" id="H1289632066"><span class="h2">Return to water recreation</span><span class="headingEndMark"> — </span>Children with diarrhea should avoid swimming and other water-related activities when they have diarrhea [<a href="#rid2">2,6,94-96</a>]. The AAP recommends that children with acute viral gastroenteritis who are not toilet trained avoid swimming for one week after diarrhea resolves [<a href="#rid96">96</a>]. NICE recommends that children should not swim in swimming pools for two weeks after the last episode of diarrhea [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H236717930"><span class="h2">Cohorting patients</span><span class="headingEndMark"> — </span>Cohorting patients refers to grouping patients with a particular type of viral gastroenteritis (eg, rotavirus) or the clinical syndrome of acute gastroenteritis according to hospital room (for multipatient rooms) or according to caregivers in the hospital. We suggest cohorting children admitted to the hospital with acute gastroenteritis to reduce secondary transmission of viral gastroenteritis pathogens [<a href="#rid88">88,89,97,98</a>]; cohorting generally continues until the last child with acute viral gastroenteritis is discharged. Other experts discourage cohorting, even if based on etiology, because of the possibility of coinfection with another pathogen [<a href="#rid1">1,99</a>]. (See  <a class="medical medical_review" href="/z/d/html/5984.html" rel="external">"Acute viral gastroenteritis in children in resource-abundant countries: Clinical features and diagnosis", section on 'Etiology'</a>.)</p><p class="headingAnchor" id="H236717625"><span class="h2">Contact isolation</span><span class="headingEndMark"> — </span>For most children hospitalized with acute viral gastroenteritis, standard and contact precautions are recommended [<a href="#rid1">1</a>]. For children with suspected viral gastroenteritis, contact precautions are recommended throughout the duration of illness for children who are in diapers or are incontinent [<a href="#rid92">92,100</a>]. For children with suspected norovirus gastroenteritis, contact precautions should be extended until 48 hours after symptoms resolve [<a href="#rid93">93</a>]. (See  <a class="medical medical_review" href="/z/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection", section on 'Standard precautions'</a> and  <a class="medical medical_review" href="/z/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection", section on 'Contact precautions'</a>.)</p><p>In the community, preventive measures to reduce contact with infected persons are, at best, partially effective. Asymptomatic infections play an important role in the spread of infection [<a href="#rid88">88,101,102</a>]. Virus excretion at levels below detection by conventional assays is well established for enteric viruses. In addition, virus excretion can begin before symptoms occur and persist after symptoms resolve. This combination of factors often obscures the source of exposure in individual cases or outbreaks.</p><p class="headingAnchor" id="H838736723"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110029.html" rel="external">"Society guideline links: Acute diarrhea in children"</a>.)</p><p class="headingAnchor" id="H27651071"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16941.html" rel="external">"Patient education: Viral gastroenteritis in adults (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/15386.html" rel="external">"Patient education: Diarrhea in children (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16587.html" rel="external">"Patient education: Giving your child over-the-counter medicines (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/17044.html" rel="external">"Patient education: Rotavirus infection (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/1202.html" rel="external">"Patient education: Acute diarrhea in children (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H29"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supportive treatment</strong> – Acute viral gastroenteritis usually is self-limited. It is treated with supportive measures (eg, fluid repletion and unrestricted diet). No specific antiviral agents are available for the treatment of acute viral gastroenteritis. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fluid repletion and maintenance</strong> – Fluid repletion and replacement of ongoing fluid losses are the goals of therapy for acute viral gastroenteritis, whether the child is managed at home, in the emergency department, or in the hospital. Fluid repletion is based upon the degree of hypovolemia (dehydration) and presence of hyper- or hyponatremia  (<a class="graphic graphic_table graphicRef76198" href="/z/d/graphic/76198.html" rel="external">table 1</a>). Severe hypovolemia requires rapid intravenous isotonic fluid resuscitation. Oral rehydration therapy (ORT) is the preferred first-line treatment for children with mild to moderate hypovolemia. (See  <a class="medical medical_review" href="/z/d/html/6142.html" rel="external">"Clinical assessment of hypovolemia (dehydration) in children"</a> and  <a class="medical medical_review" href="/z/d/html/6103.html" rel="external">"Treatment of hypovolemia (dehydration) in children in resource-abundant settings"</a> and  <a class="medical medical_review" href="/z/d/html/6129.html" rel="external">"Oral rehydration therapy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diet</strong> – We recommend resumption of an age-appropriate diet, as tolerated, as soon as rehydration is complete (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Breastfeeding can continue during diarrhea. Within the age-appropriate diet, complex carbohydrates, lean meats, yogurt, fruits, and vegetables are better tolerated than foods containing high levels of fats and simple sugars. (See <a class="local">'Diet'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptomatic therapy</strong> – Viral gastroenteritis is usually an acute and self-limited disease that does not require pharmacologic therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antidiarrheal agents – We suggest not using antidiarrheal agents (eg, antimotility drugs, antisecretory drugs, adsorbents) in the treatment of acute viral gastroenteritis (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Evidence of efficacy is weak and there is potential for serious side effects. (See <a class="local">'Antidiarrheal agents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antiemetic agents – For the routine management of children with acute viral gastroenteritis who are not dehydrated, we suggest against <a class="drug drug_pediatric" data-topicid="12659" href="/z/d/drug information/12659.html" rel="external">ondansetron</a> and other antiemetics (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2">For children ≥6 months of age with suspected or confirmed viral gastroenteritis, mild to moderate dehydration  (<a class="graphic graphic_table graphicRef76198" href="/z/d/graphic/76198.html" rel="external">table 1</a>), and vomiting that interferes with ORT, we suggest oral <a class="drug drug_pediatric" data-topicid="12659" href="/z/d/drug information/12659.html" rel="external">ondansetron</a> rather than other antiemetic agents (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Ondansetron is superior to other antiemetics in stopping vomiting facilitating ORT. The typical regimen is<strong> </strong>a single oral dose of ondansetron 0.15 mg/kg (maximum dose of 8 mg). (See <a class="local">'Antiemetic agents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Probiotics/prebiotics – Although we generally discourage probiotics and prebiotics, we make decisions on a case-by-case basis. The evidence of benefit is inconsistent. (See <a class="local">'Probiotics and prebiotics'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Zinc – We suggest not using zinc in the management of acute viral gastroenteritis in children in resource-abundant countries (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Zinc'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Criteria for discharge from the medical setting</strong> – For children who are admitted to the hospital for intravenous (IV) fluid repletion or cared for in a medical setting (eg, emergency department, office), minimum criteria for discharge to home include (see <a class="local">'Discharge from the medical setting'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Repletion of fluid status, indicated by weight gain and improvement in clinical status</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ability to meet maintenance fluid needs with oral intake (eg, volume of oral intake equals or surpasses output) (see  <a class="medical medical_review" href="/z/d/html/6122.html" rel="external">"Maintenance intravenous fluid therapy in children"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Follow-up (in person or by phone) is arranged</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Parents/caregivers understand indications to return to medical care</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Failure to respond or worsening condition</strong> – Conditions other than acute viral gastroenteritis must be considered in children who fail to respond to fluid therapy or whose clinical condition worsens despite fluid therapy. (See  <a class="medical medical_review" href="/z/d/html/5984.html" rel="external">"Acute viral gastroenteritis in children in resource-abundant countries: Clinical features and diagnosis", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/6456.html" rel="external">"Diagnostic approach to diarrhea in children in resource-abundant settings"</a> and  <a class="medical medical_review" href="/z/d/html/5902.html" rel="external">"Approach to the infant or child with nausea and vomiting"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – Measures to prevent acute viral gastroenteritis include rotavirus vaccine, handwashing with soap and water, proper diaper disposal, disinfection of water obtained from unsafe water sources, exclusion of symptomatic children from child care or school, cohorting sick children, and contact precautions for hospitalized children. (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="headingAnchor" id="H30"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledge David O Matson, MD, PhD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Guarino A, Ashkenazi S, Gendrel D, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. J Pediatr Gastroenterol Nutr 2014; 59:132.</a></li><li class="breakAll">National Institute for Health and Care Excellence. Diarrhoea and vomiting in children: Diarrhoea and vomiting caused by gastroenteritis: diagnosis, assessment and management in children younger than 5 years. https://www.nice.org.uk/guidance/cg84 (Accessed on May 26, 2017).</li><li><a class="nounderline abstract_t">King CK, Glass R, Bresee JS, et al. Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. MMWR Recomm Rep 2003; 52:1.</a></li><li><a class="nounderline abstract_t">Velázquez FR, Matson DO, Calva JJ, et al. Rotavirus infection in infants as protection against subsequent infections. N Engl J Med 1996; 335:1022.</a></li><li class="breakAll">World Gastroenterology Organisation Global Guidelines. Acute diarrhea in adults and children: A global perspective. February 2012. www.worldgastroenterology.org/acute-diarrhea-in-adults.html (Accessed on July 29, 2015).</li><li><a class="nounderline abstract_t">Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Clin Infect Dis 2017; 65:e45.</a></li><li class="breakAll">World Gastroenterology Organisation. WGO Practice Guideline - Probiotics and Prebiotics www.worldgastroenterology.org/probiotics-prebiotics.html (Accessed on July 29, 2015).</li><li><a class="nounderline abstract_t">Harris C, Wilkinson F, Mazza D, et al. Evidence based guideline for the management of diarrhoea with or without vomiting in children. Aust Fam Physician 2008; 37:22.</a></li><li><a class="nounderline abstract_t">Granado-Villar D, Cunill-De Sautu B, Granados A. Acute gastroenteritis. Pediatr Rev 2012; 33:487.</a></li><li><a class="nounderline abstract_t">Gregorio GV, Dans LF, Silvestre MA. Early versus Delayed Refeeding for Children with Acute Diarrhoea. Cochrane Database Syst Rev 2011; :CD007296.</a></li><li><a class="nounderline abstract_t">Khin MU, Nyunt-Nyunt-Wai, Myo-Khin, et al. Effect on clinical outcome of breast feeding during acute diarrhoea. Br Med J (Clin Res Ed) 1985; 290:587.</a></li><li><a class="nounderline abstract_t">Elliott EJ. Acute gastroenteritis in children. BMJ 2007; 334:35.</a></li><li><a class="nounderline abstract_t">Alarcon P, Montoya R, Perez F, et al. Clinical trial of home available, mixed diets versus a lactose-free, soy-protein formula for the dietary management of acute childhood diarrhea. J Pediatr Gastroenterol Nutr 1991; 12:224.</a></li><li><a class="nounderline abstract_t">MacGillivray S, Fahey T, McGuire W. Lactose avoidance for young children with acute diarrhoea. Cochrane Database Syst Rev 2013; :CD005433.</a></li><li><a class="nounderline abstract_t">Brown JW. Toxic megacolon associated with loperamide therapy. JAMA 1979; 241:501.</a></li><li><a class="nounderline abstract_t">Curtis JA, Goel KM. Lomotil poisoning in children. Arch Dis Child 1979; 54:222.</a></li><li><a class="nounderline abstract_t">Li ST, Grossman DC, Cummings P. Loperamide therapy for acute diarrhea in children: systematic review and meta-analysis. PLoS Med 2007; 4:e98.</a></li><li><a class="nounderline abstract_t">Florez ID, Veroniki AA, Al Khalifah R, et al. Comparative effectiveness and safety of interventions for acute diarrhea and gastroenteritis in children: A systematic review and network meta-analysis. PLoS One 2018; 13:e0207701.</a></li><li><a class="nounderline abstract_t">DuPont HL, Hornick RB. Adverse effect of lomotil therapy in shigellosis. JAMA 1973; 226:1525.</a></li><li><a class="nounderline abstract_t">Pickering LK, Obrig TG, Stapleton FB. Hemolytic-uremic syndrome and enterohemorrhagic Escherichia coli. Pediatr Infect Dis J 1994; 13:459.</a></li><li><a class="nounderline abstract_t">Figueroa-Quintanilla D, Salazar-Lindo E, Sack RB, et al. A controlled trial of bismuth subsalicylate in infants with acute watery diarrheal disease. N Engl J Med 1993; 328:1653.</a></li><li><a class="nounderline abstract_t">Pickering LK, Feldman S, Ericsson CD, Cleary TG. Absorption of salicylate and bismuth from a bismuth subsalicylate--containing compound (Pepto-Bismol). J Pediatr 1981; 99:654.</a></li><li><a class="nounderline abstract_t">Gordon M, Akobeng A. Racecadotril for acute diarrhoea in children: systematic review and meta-analyses. Arch Dis Child 2016; 101:234.</a></li><li><a class="nounderline abstract_t">Liang Y, Zhang L, Zeng L, et al. Racecadotril for acute diarrhoea in children. Cochrane Database Syst Rev 2019; 12:CD009359.</a></li><li><a class="nounderline abstract_t">Moré J, Bénazet F, Fioramonti J, Droy-Lefaix MT. Effects of treatment with smectite on gastric and intestinal glycoproteins in the rat: a histochemical study. Histochem J 1987; 19:665.</a></li><li><a class="nounderline abstract_t">Brouillard MY, Rateau JG. [Adsorption potency of 2 clays, smectite and kaolin on bacterial enterotoxins. In vitro study in cell culture and in the intestine of newborn mice]. Gastroenterol Clin Biol 1989; 13:18.</a></li><li><a class="nounderline abstract_t">Pérez-Gaxiola G, Cuello-García CA, Florez ID, Pérez-Pico VM. Smectite for acute infectious diarrhoea in children. Cochrane Database Syst Rev 2018; 4:CD011526.</a></li><li><a class="nounderline abstract_t">Freedman SB, Soofi SB, Willan AR, et al. Oral Ondansetron Administration to Nondehydrated Children With Diarrhea and Associated Vomiting in Emergency Departments in Pakistan: A Randomized Controlled Trial. Ann Emerg Med 2019; 73:255.</a></li><li><a class="nounderline abstract_t">Freedman SB, Adler M, Seshadri R, Powell EC. Oral ondansetron for gastroenteritis in a pediatric emergency department. N Engl J Med 2006; 354:1698.</a></li><li><a class="nounderline abstract_t">Tomasik E, Ziółkowska E, Kołodziej M, Szajewska H. Systematic review with meta-analysis: ondansetron for vomiting in children with acute gastroenteritis. Aliment Pharmacol Ther 2016; 44:438.</a></li><li><a class="nounderline abstract_t">Niño-Serna LF, Acosta-Reyes J, Veroniki AA, Florez ID. Antiemetics in Children With Acute Gastroenteritis: A Meta-analysis. Pediatrics 2020; 145.</a></li><li><a class="nounderline abstract_t">Fugetto F, Filice E, Biagi C, et al. Single-dose of ondansetron for vomiting in children and adolescents with acute gastroenteritis-an updated systematic review and meta-analysis. Eur J Pediatr 2020; 179:1007.</a></li><li><a class="nounderline abstract_t">Carter B, Fedorowicz Z. Antiemetic treatment for acute gastroenteritis in children: an updated Cochrane systematic review with meta-analysis and mixed treatment comparison in a Bayesian framework. BMJ Open 2012; 2.</a></li><li><a class="nounderline abstract_t">Freedman SB, Uleryk E, Rumantir M, Finkelstein Y. Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. Ann Emerg Med 2014; 64:19.</a></li><li><a class="nounderline abstract_t">Brenner SM, Boucher J. Fatal Cardiac Arrest in 2 Children: Possible Role of Ondansetron. Pediatr Emerg Care 2016; 32:779.</a></li><li><a class="nounderline abstract_t">Levine DA. Antiemetics for acute gastroenteritis in children. Curr Opin Pediatr 2009; 21:294.</a></li><li><a class="nounderline abstract_t">Ruff P, Paska W, Goedhals L, et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group. Oncology 1994; 51:113.</a></li><li><a class="nounderline abstract_t">Khan RB. Migraine-type headaches in children receiving chemotherapy and ondansetron. J Child Neurol 2002; 17:857.</a></li><li><a class="nounderline abstract_t">Garsed K, Chernova J, Hastings M, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut 2014; 63:1617.</a></li><li><a class="nounderline abstract_t">Olver I, Paska W, Depierre A, et al. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group. Ann Oncol 1996; 7:945.</a></li><li><a class="nounderline abstract_t">Sturm JJ, Hirsh DA, Schweickert A, et al. Ondansetron use in the pediatric emergency department and effects on hospitalization and return rates: are we masking alternative diagnoses? Ann Emerg Med 2010; 55:415.</a></li><li><a class="nounderline abstract_t">Benary D, Lozano JM, Higley R, Lowe D. Ondansetron Prescription Is Associated With Reduced Return Visits to the Pediatric Emergency Department for Children With Gastroenteritis. Ann Emerg Med 2020; 76:625.</a></li><li><a class="nounderline abstract_t">McLaren SH, Yim RB, Fleegler EW. Impact of Ondansetron Prescription on Return Emergency Department Visits Among Children with Acute Gastroenteritis. Pediatr Emerg Care 2021; 37:e1087.</a></li><li><a class="nounderline abstract_t">Gener B, Burns JM, Griffin S, Boyer EW. Administration of ondansetron is associated with lethal outcome. Pediatrics 2010; 125:e1514.</a></li><li class="breakAll">US Food and Drug Administration. Zofran (ondansetron): Drug Safety Communication - Risk of Abnormal Heart Rhythms. www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm272041.htm (Accessed on September 20, 2011).</li><li class="breakAll">US Food and Drug Administration. FDA Drug Safety Communication: New information regarding QT prolongation with ondansetron (Zofran) https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-new-information-regarding-qt-prolongation-ondansetron-zofran (Accessed on December 01, 2021).</li><li class="breakAll">Zofran (ondansetron) for oral use. US Food and Drug Administration (FDA) approved product information. Revised October, 2021. US National Library of Medicine. Available online at https://dailymed.nlm.nih.gov/dailymed/ (Accessed on December 07, 2021).</li><li class="breakAll">Canadian Pediatric Society. Emergency department use of oral ondansetron for acute gastroenteritis-related vomiting in infants and children. December 2018. https://cps.ca/en/documents/position/oral-ondansetron (Accessed on December 01, 2021).</li><li><a class="nounderline abstract_t">DeCamp LR, Byerley JS, Doshi N, Steiner MJ. Use of antiemetic agents in acute gastroenteritis: a systematic review and meta-analysis. Arch Pediatr Adolesc Med 2008; 162:858.</a></li><li><a class="nounderline abstract_t">Leitz G, Hu P, Appiani C, et al. Safety and Efficacy of Low-dose Domperidone for Treating Nausea and Vomiting Due to Acute Gastroenteritis in Children. J Pediatr Gastroenterol Nutr 2019; 69:425.</a></li><li><a class="nounderline abstract_t">Romano C, Dipasquale V, Scarpignato C. Antiemetic Drug Use in Children: What the Clinician Needs to Know. J Pediatr Gastroenterol Nutr 2019; 68:466.</a></li><li><a class="nounderline abstract_t">Carey MJ, Aitken ME. Diverse effects of antiemetics in children. N Z Med J 1994; 107:452.</a></li><li class="breakAll">Phenergan (promethazine HCl) tablets and suppositories [package insert]. Philadelphia: Wyeth Pharmaceuticals Inc.</li><li><a class="nounderline abstract_t">van Noord C, Dieleman JP, van Herpen G, et al. Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Saf 2010; 33:1003.</a></li><li><a class="nounderline abstract_t">Ehrenpreis ED, Roginsky G, Alexoff A, Smith DG. Domperidone is Commonly Prescribed With QT-Interacting Drugs: Review of a Community-based Practice and a Postmarketing Adverse Drug Event Reporting Database. J Clin Gastroenterol 2017; 51:56.</a></li><li><a class="nounderline abstract_t">Gibson GR, Hutkins R, Sanders ME, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol 2017; 14:491.</a></li><li><a class="nounderline abstract_t">Szajewska H, Guarino A, Hojsak I, et al. Use of Probiotics for the Management of Acute Gastroenteritis in Children: An Update. J Pediatr Gastroenterol Nutr 2020; 71:261.</a></li><li><a class="nounderline abstract_t">Collinson S, Deans A, Padua-Zamora A, et al. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev 2020; 12:CD003048.</a></li><li><a class="nounderline abstract_t">Szajewska H, Kołodziej M, Gieruszczak-Białek D, et al. Systematic review with meta-analysis: Lactobacillus rhamnosus GG for treating acute gastroenteritis in children - a 2019 update. Aliment Pharmacol Ther 2019; 49:1376.</a></li><li><a class="nounderline abstract_t">Szajewska H, Kołodziej M, Zalewski BM. Systematic review with meta-analysis: Saccharomyces boulardii for treating acute gastroenteritis in children-a 2020 update. Aliment Pharmacol Ther 2020; 51:678.</a></li><li><a class="nounderline abstract_t">Patro-Gołąb B, Szajewska H. Systematic Review with Meta-Analysis: Lactobacillus reuteri DSM 17938 for Treating Acute Gastroenteritis in Children. An Update. Nutrients 2019; 11.</a></li><li><a class="nounderline abstract_t">Quigley EMM. Editorial: Lactobacillus GG for diarrhoea in children-reports of its demise have been premature! Aliment Pharmacol Ther 2019; 49:1533.</a></li><li><a class="nounderline abstract_t">Schnadower D, Tarr PI, Freedman SB. Letter: Lactobacillus rhamnosus GG offers no benefit over placebo in children with acute gastroenteritis. Aliment Pharmacol Ther 2019; 50:620.</a></li><li><a class="nounderline abstract_t">Thomas DW, Greer FR, American Academy of Pediatrics Committee on Nutrition, American Academy of Pediatrics Section on Gastroenterology, Hepatology, and Nutrition. Probiotics and prebiotics in pediatrics. Pediatrics 2010; 126:1217.</a></li><li><a class="nounderline abstract_t">Sniffen JC, McFarland LV, Evans CT, Goldstein EJC. Choosing an appropriate probiotic product for your patient: An evidence-based practical guide. PLoS One 2018; 13:e0209205.</a></li><li><a class="nounderline abstract_t">LaMont JT. Probiotics for Children with Gastroenteritis. N Engl J Med 2018; 379:2076.</a></li><li><a class="nounderline abstract_t">Freedman SB, Finkelstein Y, Pang XL, et al. Pathogen-Specific Effects of Probiotics in Children With Acute Gastroenteritis Seeking Emergency Care: A Randomized Trial. Clin Infect Dis 2022; 75:55.</a></li><li><a class="nounderline abstract_t">Venugopalan V, Shriner KA, Wong-Beringer A. Regulatory oversight and safety of probiotic use. Emerg Infect Dis 2010; 16:1661.</a></li><li class="breakAll">CDC Health Advisory. Fatal gastrointestinal mucormycosis in an infant following ingestion of contaminated dietary supplement - Connecticut, 2014. http://emergency.cdc.gov/HAN/han00373.asp (Accessed on August 05, 2015).</li><li><a class="nounderline abstract_t">Lewis ZT, Shani G, Masarweh CF, et al. Validating bifidobacterial species and subspecies identity in commercial probiotic products. Pediatr Res 2016; 79:445.</a></li><li><a class="nounderline abstract_t">Bafeta A, Koh M, Riveros C, Ravaud P. Harms Reporting in Randomized Controlled Trials of Interventions Aimed at Modifying Microbiota: A Systematic Review. Ann Intern Med 2018; 169:240.</a></li><li><a class="nounderline abstract_t">Kolaček S, Hojsak I, Berni Canani R, et al. Commercial Probiotic Products: A Call for Improved Quality Control. A Position Paper by the ESPGHAN Working Group for Probiotics and Prebiotics. J Pediatr Gastroenterol Nutr 2017; 65:117.</a></li><li><a class="nounderline abstract_t">Freedman SB, Williamson-Urquhart S, Farion KJ, et al. Multicenter Trial of a Combination Probiotic for Children with Gastroenteritis. N Engl J Med 2018; 379:2015.</a></li><li><a class="nounderline abstract_t">Schnadower D, Tarr PI, Casper TC, et al. Lactobacillus rhamnosus GG versus Placebo for Acute Gastroenteritis in Children. N Engl J Med 2018; 379:2002.</a></li><li><a class="nounderline abstract_t">Nixon AF, Cunningham SJ, Cohen HW, Crain EF. The effect of Lactobacillus GG on acute diarrheal illness in the pediatric emergency department. Pediatr Emerg Care 2012; 28:1048.</a></li><li><a class="nounderline abstract_t">Szajewska H, Berni Canani R, Domellöf M, et al. Probiotics for the Management of Pediatric Gastrointestinal Disorders: Position Paper of the ESPGHAN Special Interest Group on Gut Microbiota and Modifications. J Pediatr Gastroenterol Nutr 2023; 76:232.</a></li><li><a class="nounderline abstract_t">Ianiro G, Rizzatti G, Plomer M, et al. Bacillus clausii for the Treatment of Acute Diarrhea in Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients 2018; 10.</a></li><li><a class="nounderline abstract_t">Bernstein DI, Atmar RL, Lyon GM, et al. Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults. J Infect Dis 2015; 211:870.</a></li><li><a class="nounderline abstract_t">Treanor JJ, Atmar RL, Frey SE, et al. A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults. J Infect Dis 2014; 210:1763.</a></li><li><a class="nounderline abstract_t">Sundararajan A, Sangster MY, Frey S, et al. Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine. Vaccine 2015; 33:568.</a></li><li><a class="nounderline abstract_t">Lindesmith LC, Ferris MT, Mullan CW, et al. Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial. PLoS Med 2015; 12:e1001807.</a></li><li><a class="nounderline abstract_t">Luby SP, Agboatwalla M, Painter J, et al. Effect of intensive handwashing promotion on childhood diarrhea in high-risk communities in Pakistan: a randomized controlled trial. JAMA 2004; 291:2547.</a></li><li><a class="nounderline abstract_t">Curtis V, Cairncross S. Effect of washing hands with soap on diarrhoea risk in the community: a systematic review. Lancet Infect Dis 2003; 3:275.</a></li><li><a class="nounderline abstract_t">Aiello AE, Coulborn RM, Perez V, Larson EL. Effect of hand hygiene on infectious disease risk in the community setting: a meta-analysis. Am J Public Health 2008; 98:1372.</a></li><li><a class="nounderline abstract_t">Ejemot-Nwadiaro RI, Ehiri JE, Arikpo D, et al. Hand washing promotion for preventing diarrhoea. Cochrane Database Syst Rev 2015; :CD004265.</a></li><li><a class="nounderline abstract_t">Payne DC, Vinjé J, Szilagyi PG, et al. Norovirus and medically attended gastroenteritis in U.S. children. N Engl J Med 2013; 368:1121.</a></li><li><a class="nounderline abstract_t">Liu P, Yuen Y, Hsiao HM, et al. Effectiveness of liquid soap and hand sanitizer against Norwalk virus on contaminated hands. Appl Environ Microbiol 2010; 76:394.</a></li><li><a class="nounderline abstract_t">Barclay L, Park GW, Vega E, et al. Infection control for norovirus. Clin Microbiol Infect 2014; 20:731.</a></li><li><a class="nounderline abstract_t">MacCannell T, Umscheid CA, Agarwal RK, et al. Guideline for the prevention and control of norovirus gastroenteritis outbreaks in healthcare settings. Infect Control Hosp Epidemiol 2011; 32:939.</a></li><li><a class="nounderline abstract_t">Clasen T, Roberts I, Rabie T, et al. Interventions to improve water quality for preventing diarrhoea. Cochrane Database Syst Rev 2006; :CD004794.</a></li><li><a class="nounderline abstract_t">Gilman RH, Skillicorn P. Boiling of drinking-water: can a fuel-scarce community afford it? Bull World Health Organ 1985; 63:157.</a></li><li class="breakAll">American Academy of Pediatric. Rotavirus infections. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatric, Itasca, IL 2021. p.644.</li><li class="breakAll">American Academy of Pediatrics. Norovirus and sapovirus infections. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.548.</li><li class="breakAll">Public Health England. Guidance on infection control in schools and other childcare settings. September 2014 https://www.gov.uk/government/publications/infection-control-in-schools-poster (Accessed on July 29, 2015).</li><li class="breakAll">Centers for Disease Control and Prevention. Healthy Swimming. Diarrheal Illness. https://www.cdc.gov/healthywater/swimming/swimmers/rwi/diarrheal-illness.html (Accessed on May 22, 2017).</li><li class="breakAll">American Academy of Pediatrics. Prevention of illnesses associated with recreational water use. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.180.</li><li><a class="nounderline abstract_t">Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention. Updated norovirus outbreak management and disease prevention guidelines. MMWR Recomm Rep 2011; 60:1.</a></li><li><a class="nounderline abstract_t">Cheng FW, Leung TF, Lai RW, et al. Rapid control of norovirus gastroenteritis outbreak in an acute paediatric ward. Acta Paediatr 2006; 95:581.</a></li><li><a class="nounderline abstract_t">Valentini D, Vittucci AC, Grandin A, et al. Coinfection in acute gastroenteritis predicts a more severe clinical course in children. Eur J Clin Microbiol Infect Dis 2013; 32:909.</a></li><li class="breakAll">American Academy of Pediatrics. Adenovirus infections. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.188.</li><li><a class="nounderline abstract_t">Pickering LK, Bartlett AV 3rd, Reves RR, Morrow A. Asymptomatic excretion of rotavirus before and after rotavirus diarrhea in children in day care centers. J Pediatr 1988; 112:361.</a></li><li><a class="nounderline abstract_t">Matson DO, O'Ryan ML, Herrera I, et al. Fecal antibody responses to symptomatic and asymptomatic rotavirus infections. J Infect Dis 1993; 167:577.</a></li></ol></div><div id="topicVersionRevision">Topic 5992 Version 49.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24739189" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24739189" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14627948" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8793926" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Rotavirus infection in infants as protection against subsequent infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8793926" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Rotavirus infection in infants as protection against subsequent infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29053792" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29053792" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19142266" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Evidence based guideline for the management of diarrhoea with or without vomiting in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23118314" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Acute gastroenteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21735409" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Early versus Delayed Refeeding for Children with Acute Diarrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3918683" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effect on clinical outcome of breast feeding during acute diarrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17204802" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Acute gastroenteritis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2051273" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical trial of home available, mixed diets versus a lactose-free, soy-protein formula for the dietary management of acute childhood diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24173771" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Lactose avoidance for young children with acute diarrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/759668" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Toxic megacolon associated with loperamide therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/434909" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Lomotil poisoning in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17388664" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Loperamide therapy for acute diarrhea in children: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30517196" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Comparative effectiveness and safety of interventions for acute diarrhea and gastroenteritis in children: A systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4587313" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Adverse effect of lomotil therapy in shigellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8078733" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Hemolytic-uremic syndrome and enterohemorrhagic Escherichia coli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8487823" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A controlled trial of bismuth subsalicylate in infants with acute watery diarrheal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7277115" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Absorption of salicylate and bismuth from a bismuth subsalicylate--containing compound (Pepto-Bismol).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26715673" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Racecadotril for acute diarrhoea in children: systematic review and meta-analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31858591" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Racecadotril for acute diarrhoea in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3443559" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Effects of treatment with smectite on gastric and intestinal glycoproteins in the rat: a histochemical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2647564" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : [Adsorption potency of 2 clays, smectite and kaolin on bacterial enterotoxins. In vitro study in cell culture and in the intestine of newborn mice].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29693719" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Smectite for acute infectious diarrhoea in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30392735" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Oral Ondansetron Administration to Nondehydrated Children With Diarrhea and Associated Vomiting in Emergency Departments in Pakistan: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16625009" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Oral ondansetron for gastroenteritis in a pediatric emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27401959" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Systematic review with meta-analysis: ondansetron for vomiting in children with acute gastroenteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32132152" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Antiemetics in Children With Acute Gastroenteritis: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32382791" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Single-dose of ondansetron for vomiting in children and adolescents with acute gastroenteritis-an updated systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22815462" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Antiemetic treatment for acute gastroenteritis in children: an updated Cochrane systematic review with meta-analysis and mixed treatment comparison in a Bayesian framework.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24314899" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27814325" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Fatal Cardiac Arrest in 2 Children: Possible Role of Ondansetron.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19381093" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Antiemetics for acute gastroenteritis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8265095" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12585731" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Migraine-type headaches in children receiving chemotherapy and ondansetron.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24334242" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9006746" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20031265" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Ondansetron use in the pediatric emergency department and effects on hospitalization and return rates: are we masking alternative diagnoses?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32471647" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Ondansetron Prescription Is Associated With Reduced Return Visits to the Pediatric Emergency Department for Children With Gastroenteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31524821" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Impact of Ondansetron Prescription on Return Emergency Department Visits Among Children with Acute Gastroenteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20439600" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Administration of ondansetron is associated with lethal outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20439600" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Administration of ondansetron is associated with lethal outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20439600" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Administration of ondansetron is associated with lethal outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20439600" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Administration of ondansetron is associated with lethal outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20439600" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Administration of ondansetron is associated with lethal outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18762604" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Use of antiemetic agents in acute gastroenteritis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31181017" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Safety and Efficacy of Low-dose Domperidone for Treating Nausea and Vomiting Due to Acute Gastroenteritis in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30540713" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Antiemetic Drug Use in Children: What the Clinician Needs to Know.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7970356" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Diverse effects of antiemetics in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7970356" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Diverse effects of antiemetics in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20925438" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27182647" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Domperidone is Commonly Prescribed With QT-Interacting Drugs: Review of a Community-based Practice and a Postmarketing Adverse Drug Event Reporting Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28611480" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32349041" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Use of Probiotics for the Management of Acute Gastroenteritis in Children: An Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33295643" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Probiotics for treating acute infectious diarrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31025399" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Systematic review with meta-analysis: Lactobacillus rhamnosus GG for treating acute gastroenteritis in children - a 2019 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32056266" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Systematic review with meta-analysis: Saccharomyces boulardii for treating acute gastroenteritis in children-a 2020 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31739457" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Systematic Review with Meta-Analysis: Lactobacillus reuteri DSM 17938 for Treating Acute Gastroenteritis in Children. An Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31134655" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Editorial: Lactobacillus GG for diarrhoea in children-reports of its demise have been premature!</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31414542" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Letter: Lactobacillus rhamnosus GG offers no benefit over placebo in children with acute gastroenteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21115585" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Probiotics and prebiotics in pediatrics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30586435" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Choosing an appropriate probiotic product for your patient: An evidence-based practical guide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30462932" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Probiotics for Children with Gastroenteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34596225" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Pathogen-Specific Effects of Probiotics in Children With Acute Gastroenteritis Seeking Emergency Care: A Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21029521" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Regulatory oversight and safety of probiotic use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21029521" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Regulatory oversight and safety of probiotic use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26571226" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Validating bifidobacterial species and subspecies identity in commercial probiotic products.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30014150" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Harms Reporting in Randomized Controlled Trials of Interventions Aimed at Modifying Microbiota: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28644359" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Commercial Probiotic Products: A Call for Improved Quality Control. A Position Paper by the ESPGHAN Working Group for Probiotics and Prebiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30462939" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Multicenter Trial of a Combination Probiotic for Children with Gastroenteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30462938" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Lactobacillus rhamnosus GG versus Placebo for Acute Gastroenteritis in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23023475" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The effect of Lactobacillus GG on acute diarrheal illness in the pediatric emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36219218" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Probiotics for the Management of Pediatric Gastrointestinal Disorders: Position Paper of the ESPGHAN Special Interest Group on Gut Microbiota and Modifications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30103531" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Bacillus clausii for the Treatment of Acute Diarrhea in Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25210140" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24951828" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25444793" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25803642" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15173145" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Effect of intensive handwashing promotion on childhood diarrhea in high-risk communities in Pakistan: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12726975" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Effect of washing hands with soap on diarrhoea risk in the community: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18556606" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Effect of hand hygiene on infectious disease risk in the community setting: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26346329" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Hand washing promotion for preventing diarrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23514289" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Norovirus and medically attended gastroenteritis in U.S. children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19933337" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Effectiveness of liquid soap and hand sanitizer against Norwalk virus on contaminated hands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24813073" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Infection control for norovirus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21931246" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Guideline for the prevention and control of norovirus gastroenteritis outbreaks in healthcare settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16856059" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Interventions to improve water quality for preventing diarrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3872734" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Boiling of drinking-water: can a fuel-scarce community afford it?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3872734" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Boiling of drinking-water: can a fuel-scarce community afford it?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3872734" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Boiling of drinking-water: can a fuel-scarce community afford it?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3872734" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Boiling of drinking-water: can a fuel-scarce community afford it?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3872734" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Boiling of drinking-water: can a fuel-scarce community afford it?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3872734" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Boiling of drinking-water: can a fuel-scarce community afford it?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21368741" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Updated norovirus outbreak management and disease prevention guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16825139" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Rapid control of norovirus gastroenteritis outbreak in an acute paediatric ward.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23370970" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Coinfection in acute gastroenteritis predicts a more severe clinical course in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23370970" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Coinfection in acute gastroenteritis predicts a more severe clinical course in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2831326" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Asymptomatic excretion of rotavirus before and after rotavirus diarrhea in children in day care centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8440929" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Fecal antibody responses to symptomatic and asymptomatic rotavirus infections.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
